001360 — Samsung Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual income statement for Samsung Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	54,901	51,832	51,955	44,294	46,074
Cost of Revenue
Gross Profit	9,282	24,619	22,973	19,774	13,980
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	75,487	75,379	78,035	60,363	66,702
Operating Profit	-20,586	-23,547	-26,080	-16,069	-20,627
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-40,276	-25,093	-23,675	-14,092	11,545
Provision for Income Taxes
Net Income After Taxes	-40,276	-25,093	-24,812	-14,092	11,545
Net Income Before Extraordinary Items
Net Income	-40,276	-25,093	-24,812	-14,092	11,545
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-40,276	-25,093	-24,812	-14,092	11,545
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-494	-210	-264	-143	149
Dividends per Share